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Objective: Bronchioloalveolar lung cancer is commonly multifocal and can also
present with other non–small cell types. The staging and treatment of multifocal
non–small cell cancer are controversial. We evaluated the current staging of mul-
tifocal bronchioloalveolar carcinoma and the therapeutic effectiveness of resection
when this tumor type is involved.
Methods: We reviewed our experience between 1992 and 2000 with complete
pulmonary resections for bronchioloalveolar carcinoma. Kaplan-Meier survival
curves were calculated from the dates of pulmonary resection.
Results: Among 73 patients with bronchioloalveolar carcinoma, 14 patients, 7 male
and 7 female with a mean age of 65 years (51-87 years), had multifocal lesions
without lymph node metastases. Follow-up was 100% for a median of 5 years (range
2.6-8.5 years). Tumor distribution was unilateral in 9 patients and bilateral in 5
patients. The multifocal nature of the disease was discovered intraoperatively in 4
patients. Nine patients had 2 lesions, 4 patients had 3 lesions, and 1 patient had
innumerable discrete foci in a single lobe. Operative mortality was 0. Postopera-
tively, 10 patients were staged pIIIB or pIV on the basis of multiple foci of similar
morphology; 4 patients had some differences in histology (implying multiple stage
1 primaries). The median survival time to death from cancer was 14 months (141
days–5.6 years). The overall 5-year survival after resection of multifocal bronchi-
oloalveolar carcinoma was 64%. Unilateral or bilateral distribution had no impact
on survival.
Conclusions.The current staging system is not prognostic for multifocal bronchi-
oloalveolar carcinoma without lymph node metastases. Complete resection of
multifocal non–small cell lung cancer when bronchioloalveolar carcinoma is a
component may achieve survivals similar to that of stage I and II unifocal non–small
cell lung cancer. When bronchioloalveolar carcinoma is believed to be one of the
cell types in multifocal disease without lymph node metastases, consideration
should be given to surgical resection.
In clinical practice, the many types and subtypes of non–small cell lungcancer (NSCLC) have been treated as a single entity. The evaluation,staging, and treatment of NSCLC have been fairly standardized. Bronchi-oloalveolar carcinoma (BAC) of the lung is a subtype of adenocarcinomathat has enough distinct clinical features to justify special considerationwhen offering a prognosis. With the rising incidence of BAC,1 thoracic
surgeons will be faced with increasing preoperative diagnoses of BAC, thus allow-
ing time to formulate a treatment plan tailored for this specific lesion.
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BAC has a lepidic growth pattern along alveolar walls.
Computed tomography (CT) typically shows either a nod-
ular type or diffuse infiltrative type of growth pattern.
Malassez2 described the diffuse type in 1876 and associated
it with a poor prognosis. In 1960, Liebow3 noted the asso-
ciation of the small peripheral airways and alveolar spaces
and introduced the term “bronchioloalveolar carcinoma.”
BAC has been further subdivided into mucinous and non-
mucinous types. BAC may present as a multifocal process;
the reported incidence is as high as 25%.1 Multiple tumor
types can exist in a synchronous fashion with BAC.
The staging and treatment of multifocal lung cancer have
been controversial, at least in part because it can be hard to
differentiate multiple sites of primary cancer from intrapul-
monary metastases (IPMs).4 Related to this issue are 2
alterations in the staging system of lung cancer that have
occurred in the last decade. In 1992, the Union Internatio-
nale Contre le Cancer and the American Joint Committee on
Cancer revised the TNM classification for lung cancer and
classified IPMs as local progression rather than distant
metastases.4,5 In 1997, another change was introduced:
IPMs were to be designated as T4 lesions when they oc-
curred in the same lobe as the primary tumor, therefore
placing patients with IPMs in the same lobe in stage IIIB.6
IPMs in all other lobes were designated as distant metasta-
ses, M1, and therefore stage IV disease. At present there is
no standardized technique of determining monoclonality.
What outcome might one expect after complete resection
of multifocal NSCLC without lymph node metastases (N0)?
Two recently published studies attempted to further clarify
this issue. Batafarano and colleagues7 have reported encour-
aging results after complete surgical resection of multifocal
NSCLC, but their data regarding BAC and combinations of
tumor types was limited. Ebright and colleagues8 reviewed
their experience with multifocal BAC and concluded that
even patients in the advanced stage should undergo resec-
tion. They included only BAC pathology. We reviewed our
experience to gain further insight on a limited body of
literature regarding the adequacy of the current staging
system to predict survival in multifocal BAC. Furthermore,
there are increasing data to support the belief that BAC has
an independently favorable prognosis when compared with
other NSCLC.8 Therefore, one would expect survival to be
higher in a subgroup of patients with multifocal disease
when BAC is involved.
Methods
The study was performed retrospectively on patients who under-
went resection at a single institution. Our surgical pathology da-
tabase of all resected lung specimens was searched from 1992 to
2000 for all patients whose final diagnoses included BAC or
adenocarcinoma with foci of BAC.
BAC was diagnosed according to the recent World Health
Organization criteria9 when a bronchioloalveolar growth pattern
occurred without stromal, vascular, or pleural invasion. Patients
with multifocal disease were identified and underwent a more
detailed chart review. Multifocal disease was defined as 2 or more
foci of tumor separated by normal lung tissue. Tumors that differed
histologically were designated as multiple primary tumors. When
tumors were histologically similar, they were designated as IPMs.
Only patients who underwent a complete resection with curative
intent were included in the study. A thorough review of the
medical records was performed on these patients, and pathologic
diagnosis was again confirmed in this group. Patients with a
preoperative diagnosis of N2 disease received induction therapy
and therefore were not included in the study. In addition, patients
who underwent operations with the intent of only diagnosis (bi-
opsies) and patients who were discovered to have a positive
margin were not included.
Preoperative workup in all patients included chest CT scanning
from lung apex to adrenal glands. Complete mediastinal lymph
node sampling was performed at all operations. Patients were
staged according to the current TNM classification.6 Follow-up
was achieved with chart reviews and telephone contact when the
most recent office visit was more than 6 months before the review.
Dates of death were established through family members and the
Social Security Death Index.
Survival was calculated by the Kaplan-Meier estimation using
the date of initial pulmonary resection and date of death or last
contact as the beginning and end points. Differences in survival
were calculated using log-rank analysis.
Results
Between 1992 and 2000, 105 patients with BAC were
found. Thirty-two of these underwent only biopsies or in-
complete resections and were therefore excluded from the
study. Seventy-three patients underwent complete pulmo-
nary resections for at least 1 focus of BAC.
Fourteen patients, 7 men and 7 women with a mean age
of 65 years (range 51-87 years), were identified who had N0
multifocal disease (T1-T4). Nine patients had unilateral
BAC, and 5 patients had bilateral lesions. Follow-up in the
study was 100%. Median duration of follow-up of the 8
currently living patients was 5 years (range 2.6-8.5 years).
The 14 patients are summarized in Figure 1.
Preoperative Diagnosis
In 10 cases, the multifocal nature of the disease was known
preoperatively. In 4 cases, the multifocal nature of the
disease was discovered intraoperatively and postopera-
tively. Three of these cases occurred early in the study when
CT scanners with comparatively low resolution were being
used.
Operations
Fourteen patients had 30 pulmonary resections in 18 oper-
ations including 7 unilateral thoracotomies, 2 video-assisted
resections, 2 median sternotomies (each requiring a subse-
quent thoracotomy), 2 staged bilateral thoracotomies, and 1
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same-day bilateral thoracotomy. There were 12 lobecto-
mies, 15 wedge resections, and 3 formal segmentectomies.
Among the 5 patients with bilateral BAC, 2 underwent
sternotomies, including 1 patient who underwent a complete
resection with a segmentectomy and 2 wedge resections.
The second patient underwent a right upper lobectomy
through a sternotomy, but the planned left lower lobectomy
could not be safely and completely resected through that
incision. Accordingly, left lower lobectomy was performed
2 months later. Three patients underwent bilateral thoracot-
omies, including 1 single operation and 2 staged procedures
at 2- and 3-month intervals.
There were no operative deaths. Two serious complica-
tions (14%) included a deep venous thrombosis and pulmo-
nary embolism in 1 patient and an empyema in 1 patient.
Both patients recovered fully. The single minor complica-
tion was a delayed pneumothorax after 3 wedge resections.
Pathologic Findings
Nine patients had 2 foci of cancer, 4 patients had 3 foci, and
1 patient had many discrete foci of BAC within a single
lobe. The 14 patients were staged in the following way. Two
patients were staged IIIB on the basis of multiple lesions
within the same lobe. Eight patients had stage IV disease on
the basis of foci of BAC in multiple lobes. Two patients had
clearly different pathology in the second foci, a neuroendo-
crine tumor in 1, and a poorly differentiated large cell tumor
in the other, which were therefore multiple stage I carcino-
mas. The final 2 patients had a combination of adenocarci-
noma with BAC features in 1 tumor and pure BAC in the
other lesion(s). These patients were staged with independent
tumors. No patients had mediastinal lymph node involve-
ment.
Two patients had a history of lung cancers, both approx-
imately 2 years before resection of N0 multifocal BAC. The
first patient was a 70-year-old woman who had been treated
for a limited small cell cancer with wedge resection and
postoperative chemotherapy. Her multifocal disease oc-
curred 2 years later and was found at resection to have both
a focus of BAC and a neuroendocrine tumor; both were
completely resected. She remains disease-free at 2.8 years
follow-up. The second patient was a 69-year-old man who
had undergone resection for an adenocarcinoma that was
histologically different from his subsequent cancers. When
his multifocal BAC presented 2 years later, he underwent a
completion right upper lobectomy. He developed tumor
recurrence initially confined to the thorax 3 years later and
elected not to undergo treatment. He has had slowly pro-
gressing disease for 2 years.
A 68-year-old woman also had developed a recurrence
4.6 years after her original sternotomy for bilateral BAC.
She elected to undergo re-resection for her new foci of
BAC. She tolerated this well, but when it recurred 2 years
later she opted not to receive any further treatment. She
remains active 6.7 years after her initial resection without
any evidence of extrathoracic disease. It is interesting that
she had been followed for 2 years before her initial resection
for what was her slowly increasing BAC. This patient
illustrates the often insidious nature of some types of BAC.
Five patients died of tumor recurrence. Two patients with
non-BAC histology had extrathoracic spread before their
death. Their median survival was 14 months (range 141
days–5.6 years). The patient who died 5 months postoper-
atively had a very aggressive form of BAC. No patient with
lethal tumor recurrence underwent chemotherapy or radia-
tion. The final death in the group was a patient who died as
a result of pancreatic cancer 1 year after the pulmonary
resection.
The overall survival in the study group was 64% at 5
years (Figure 2). Currently, 6 patients are alive and well
without known recurrence of BAC or any other type of lung
cancer. Two of the surviving 8 patients have known tumor
recurrence and are alive at more than 5 years after their
initial resection. There was no difference in survival related
to the number of or distribution of lesions.
Discussion
Most patients with BAC in our study were designated with
advanced disease because they were in stage IIIB or stage
IV according to current staging nomenclature. Four patients
had multiple primary tumors. The expected 5-year survival
for NSCLC in stages IIIB and IV is approximately 5% and
Figure 1. Outcome of the 14 patients with unilateral and bilateral
distribution of their tumors. NED, No evidence of disease.
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less than 1%, respectively.10 The survival of 64% in our
study greatly exceeds this and is much greater than reports
for survival in non-BAC multifocal disease. Vansteenkiste
and coworkers11 reported a 5-year survival of 33% when all
cell types were considered. This indicates a serious defi-
ciency in applying the current staging system to multifocal
disease if BAC is involved. As Ebright and colleagues8
claimed, this does not seem to depend on the BAC subtype.
Evaluating the validity of staging systems is important
because staging criteria evolve as a result of compiled
experience. After the 1997 revisions, Okada and associ-
ates12 evaluated 89 patients who had ipsilateral IPMs. All
patients by definition were either in stage IIIB or stage IV.
By using the 1997 system, they compared patients with
stage III and IV disease with and without IPMs. Patients
with stage IV disease on the basis of metastases to a lung
lobe other than the one that had contained the primary
metastasis had significantly better survival than patients
who were in stage IV because of other sites of metastasis.
Within the IIIB group, there were significant survival dif-
ferences between the patients with N0, N1, and N2 disease.
In other words, Okada and coworkers confirmed that lymph
node status (N factor) was a better predictor of survival than
the number or location of IPMs that could be surgically
resected. Their findings, like ours, indicated that patients
with multifocal disease without mediastinal involvement
have a better prognosis than a patient with N2 or N3 disease.
Okada and associates also concluded that the 1997 revisions
were less acceptable than the 1992 revisions with regard to
the significance of IPM. These investigators, however, in-
tentionally avoided including BAC in their study because of
their multicentricity and unique behavior.
When Nakajima and colleagues13 reported their experi-
ence with IPM, they included patients with BAC. They
reviewed 50 patients with NSCLC who had IPMs, including
29 patients with well-differentiated adenocarcinoma with
bronchoalveolar spread. Patients without vascular or lym-
phatic invasion and with T status less than or equal to 2 had
significantly better survival than those who had vascular or
lymphatic invasion or T status greater than 2. Fifteen pa-
tients had BAC without vascular or lymphatic spread with a
T status less than or equal to 2; their actuarial 5-year
survival was 100% with a mean follow-up of 28 months.
Nakajima and coworkers, however, cautioned that the ex-
ceptionally high survival in their study may have been the
result of some erroneous diagnoses of BAC when atypical
adenomatous hyperplasia was actually present. Accord-
ingly, in our study we reviewed the pathology slides to
confirm the diagnosis of BAC in accordance with new
World Health Organization guidelines. The question of
multiple primary tumors (localized cancer in several places)
versus true metastasis (systemic disease) is central to un-
derstanding BAC. Barsky and colleagues1 in 1994 pub-
lished their genetic research with BAC using a novel strat-
egy for clonality determination. They determined that
tumors in these locations were mostly multiclonal indepen-
dent cancers. They further suggested that because of this
fact, lung-sparing operations (wedge resections) should be
performed. A subsequent genetic study argued for a mono-
clonal origin.14 This study involved larger numbers of pa-
tients, and because the genetic investigators believed their
data supported a truly metastatic hypothesis, they ques-
tioned the role of surgery in patients with multifocal disease.
This issue has not been evaluated in a large clinical series,
and we made no attempt to do so here. Although it is an
important biologic question, it may not be immediately
clinically relevant because the overall survival in our pa-
tients in other series8 indicates that multifocal BACs should
be resected regardless of their clonal origin.
The wide variety of clinical behaviors within BAC has
complicated the issue. Groups have reviewed their patients
in an attempt to improve the ability to predict outcome and
tailor treatment on the basis of the histologic subtype and
radiographic appearance of tumors.15 Ebright and col-
leagues8 have subsequently suggested that histologic sub-
type does not affect prognosis whereas stage and clinical
patterns do. Holst and colleagues14 noted that as patients
age they are less likely to have metastases. Dumont and
associates16 reported on a group of patients who had had
stable parenchymal lesions for 2 to 7 years (mean 4 years)
that were ultimately determined to be BACs. They had
received no treatment. These facts may indicate that elderly
patients with slow-growing lesions may be best treated with
close observation. Perhaps it is the tumor biology and not
the surgery that is accounting for survival. This is under-
scored by 2 of our patients who have experienced long-term
survival with known recurrences. Clearly some types of
Figure 2. Overall survival of 14 patients with resected multifocal
bronchoalveolar lung cancer. Survival was calculated from initial
pulmonary resection until death or last follow-up. At 5 years,
overall survival was 64%.
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BAC behave much differently than other NSCLCs. Obser-
vation of resectable lung cancer would require a new treat-
ment paradigm based on a tumor’s specific predicted be-
havior. Retrospective reviews may not be able to validate
this idea, and at the present time randomized trials do not
exist.
Conventional chemotherapy has had poor results with
BAC, but newer drugs such as epidermal growth factor
receptor-tyrosine kinase inhibitors, “Iressa,” and vaccine
therapies have shown some initial promise.17 Studies eval-
uating the role of these drugs specifically in BAC are
ongoing. Perhaps these drugs will improve survival in both
early and advanced stages of BAC. Unanswered questions
and different opinions reflect the complexities and hetero-
geneity of this tumor subtype.
Confusion would result if modifications were made to
the lung cancer staging system too frequently. This would
translate into difficulty in patient care, clinical trial devel-
opment and interpretation, and comparisons of data among
institutions. Thus, even though we believe that the current
staging system is inadequate for multifocal N0 BAC, we
continue to use it. However, we support previous reports
that indicate a need for ongoing evaluation with eventual
modifications to the staging system based on the collection
of more data. We hope that a greater understanding of
individual tumor biology will add to the clarity and accu-
racy of new staging systems that may take into account
tumor type.
On the basis of our experience, we continue to evaluate
multifocal disease when BAC is present with an eye toward
resection. Although many of these patients will be clinically
staged IIIB or IV, we recommend operation when complete
resection can be safely achieved. Even in cases of repeat
resections, long-term survival can be achieved.
We acknowledge Ronald Hayes, PA-C, and Shirley Cable for
their great assistance in data collection and preparation of this
article.
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Discussion
Dr Richard Whyte (Stanford, Calif). In this article, the authors
present the outcomes of 14 patients with multifocal BAC of the
lung. They suggest that a conventional staging system would
assign these patients to either stage IIIb or IV depending on
whether the lesions are in the same lobe or different lobes, and that
such patients would have an anticipated survival of less than 10%.
The observed survival was greater than 60%, and this clearly
indicates one of the shortcomings of the conventional staging
system. It is very helpful for us to know what happens to these
patients in the long run.
Dr Roberts, I have 3 questions for you. First, your patients with
multifocal disease seem to represent approximately 20% of the
patients with BAC whom you have seen. What happened with the
other 80%? Were they followed in the long run for many years? If
so, would you expect your 20% to actually be a significantly higher
percentage of all the patients with BAC presenting with multifocal
disease?
Dr Roberts. One deficiency of our study is that we did not
review all of the pathology slides. Perhaps some of the other
patients whom we have treated for multifocal disease in fact had
BAC, and it is true that what appears to be unifocal disease may
some day be multifocal disease or recurrence. We did not review
in detail all of our other patients with BAC, but the overall survival
of those patients does seem to be about what you would expect
with stage I NSCLC.
Dr Whyte. My second question relates to the nomenclature of
BAC. In our weekly tumor board meetings, we frequently hear
about adenocarcinoma with bronchoalveolar features versus BAC.
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